While clinical and laboratory features worsened between diagnosis and ruxolitinib start in both CALR and JAK2 patients, confirming the progressive nature of the disease, CALR-mutated patients had the greatest worsening, with a higher number of patients acquiring anemia and increasing the peripheral blast count. The gene discussed is JAK2; the disease is anemia.